#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Kathryn Brown Email
Distinguished Director Intellectual Property . Progenics Pharmaceuticals
New York, NY
LocationPrimary Email
How to contact Kathryn Brown
Join and see Kathryn's contact info for free!Phone
Current Roles
Employees:
68Revenue:
$5.3MAbout
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic which completed a two-cohort phase 2 clinical trial and a small molecule imaging agent that has also completed a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra, an ultra-orphan radiotherapy candidate currently in a phase 2 study under an SPA. Progenics first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Ltd., a Valeant Pharmaceuticals International, Inc. company. For additional information, please visit www.progenics.com.Progenics Pharmaceuticals Address
One World Trade CenterNew York, NY
United States